NEUROLOGY
Akhtar RS and Mano T.
Neurology. 2019 Feb 27 pii: 10.1212/WNL.0000000000007194
DOI: https://doi.org/10.1212/WNL.0000000000007194
Abstract
People with motor symptoms, such as involuntary tremor, slowness of movement, and gait difficulty, often first present for evaluation and diagnosis in general neurology offices. Although the first sign in Parkinson disease (PD) at an early stage varies, the diagnosis of PD is often the correct one, simply by taking account of its prevalence. However, confirmation of that diagnosis takes time and serial examinations, and it is increasingly recognized that a fraction of those diagnosed with PD actually have another movement disorder and will therefore have a different neurodegenerative disease at autopsy.1 In particular, the atypical parkinsonism disorders (APDs), such as multiple system atrophy (MSA), progressive supranuclear palsy, and corticobasal syndrome, as well as vascular parkinsonism, can mimic PD at early stages of the clinical disease. These misdiagnoses are not isolated to the general neurology practice; in fact, when the presentation is unusual or early enough, even movement disorder specialists cannot discriminate between PD and APD. As a result of these diagnostic challenges, individuals can walk away thinking they have PD, when in reality a typically more aggressive condition looms in their near future.
Related Posts
Neurology
Comparative Spatial Analyses of the Tumor Immune Landscape in Mouse Models of Glioblastoma Using the PhenoCode Discovery Mouse Neuro Panel and Customized Markers
Poster Background Developing effective therapies for glioblastoma (GBM) relies on robust preclinical animal models that enable detailed investigation of tumor biology, discovery of therapeutic targets, and evaluation of new treatment…
Oncology
Development of a Spatial Metabolic Map of Immunotherapy Sensitive and Resistant Cutaneous Skin Carcinoma
Poster Background Ultrahigh-Plex Single-cell Spatial Phenotyping has revealed valuable insights into the tumor immune microenvironment (TiME) for biomarker discovery and stratification of clinical responses. Metabolic reprogramming is a key hallmark…
Spatial Immunometabolic Profiling of Non-Small Cell Lung Cancer Reveals Distinct Immune Exclusion Patterns and Functional Niches
Analytical validation of a multiplex immunofluorescence 7-Biomarker Immunoprint® assay on the Akoya PhenoImager HT platform for stage I/II Melanoma
Neurology
Neurodegenerative biomarkers in different chambers of the eye relative to plasma: an agreement validation study
Alzheimer’s Research and Therapy | August 26, 2024 Sampani K, Ness S, Tuz-Zahra F, Aytan N, Spurlock EE, Alluri S, Chen X, Siegel NH, Alosco ML, Xia W, Tripodis Y,…
Neurology
Clinical validation of the LucentAD p-Tau 217 as a lab developed test (LDT) for clinical use
Poster The intersection of new therapeutic options for Alzheimer’s disease (AD), the emergence of accurate blood-based tests for AD, and the anticipated health system log jam for confirmatory diagnostic testing…
Neurology
Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice
Alzheimer’s & Dementia | August 3, 2024 Verberk IMW, Jutte J, Kingma MY, Vigneswaran S, Gouda MMTEE, van Engelen MP, Alcolea D, Arranz J, Fortea J, Lleó A, Chevalier C,…
Neurology
Discovering novel plasma biomarkers for ischemic stroke: Lipidomic and metabolomic analyses in an aged mouse model
Journal of Lipid Research | August 2, 2024 Becktel DA, Frye JB, Le EH, Whitman SA, Schnellmann RG, Morrison HW, Doyle KP. J Lipid Res. 2024 https://doi.org/10.1016/j.jlr.2024.100614 Abstract Ischemic stroke…